Basiliximab Does Not Impair Airway Mucociliary Clearance of Rats

Imagem de Miniatura
Arquivos
art_CORREIA_Basiliximab_Does_Not_Impair_Airway_Mucociliary_Clearance_of_2022.PDF (2.05 MB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER/PLENUM PUBLISHERS
Autores
NOLASCO, Patricia
SOUZA, Maria Cecilia Ribeiro de
Citação
INFLAMMATION, v.45, n.6, p.2243-2255, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Previous studies have shown that immunosuppressive drugs impair the airway mucociliary clearance of rats. However, considering the high specificity of basiliximab (BSX) and the absence of studies reporting its side effects, our aim was to investigate whether BSX, associated or not with triple therapy, impairs the mucociliary system. Forty rats were divided into 4 groups: Control, BSX, Triple, and BSX + Triple. After 15 days of treatment, animals were euthanized and the ciliary beating frequency (CBF), mucociliary transport velocity (MCTV), neutral and acid mucin production, Muc5ac and Muc5b gene expression, inflammatory cell number, and interleukin (IL)-6 concentration were analyzed. CBF and MCTV were lower in Triple and BSX + Triple groups (p < 0.05). Neutral mucin percentage was higher in Triple group (p < 0.05), and acid mucin percentage was higher in Triple and BSX + Triple groups (p < 0.05). The Muc5ac and Muc5b gene expression was higher in Triple and BSX + Triple groups (p < 0.05). Animals from Triple and BSX + Triple groups presented fewer mononuclear cells (p < 0.05). The number of polymorphonuclear cells was higher in the Triple group (p < 0.05). In the analysis of inflammatory cells in the blood, there was a decrease in lymphocytes and an increase in neutrophils in the Triple and BSX + Triple groups (p < 0.05). The concentration of IL-6 significantly increased in the animals of the Triple and BSX + Triple groups (p < 0.05). BSX did not change the mucociliary apparatus of rats.
Palavras-chave
basiliximab, mucin-5AC, mucin-5B, mucociliary clearance, calcineurin inhibitor
URI
https://observatorio.fm.usp.br/handle/OPI/50461
Referências
  1. AEBA R, 1993, J THORAC CARDIOV SUR, V106, P449
  2. Antunes MB, 2007, CURR OPIN ALLERGY CL, V7, P5, DOI 10.1097/ACI.0b013e3280114eef
  3. Beaver BV, 2001, J AM VET MED ASSOC, V218, P669, DOI 10.2460/javma.2001.218.669
  4. Chapman TM, 2003, DRUGS, V63, P2803, DOI 10.2165/00003495-200363240-00009
  5. Chatterjee M, 2020, MBIO, V11, DOI 10.1128/mBio.02374-20
  6. Chen Y, 2003, J BIOL CHEM, V278, P17036, DOI 10.1074/jbc.M210429200
  7. CLARKE SW, 1980, BRIT J CLIN PHARMACO, V9, P537, DOI 10.1111/j.1365-2125.1980.tb01078.x
  8. Crawford S W, 1995, Curr Opin Pulm Med, V1, P209
  9. Braga KAD, 2012, CLINICS, V67, P647, DOI 10.6061/clinics/2012(06)16
  10. Denneny E, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1120
  11. Fahy JV, 2010, NEW ENGL J MED, V363, P2233, DOI 10.1056/NEJMra0910061
  12. Fernandes Paulo Manuel Pêgo, 2008, J. bras. pneumol., V34, P273, DOI 10.1590/S1806-37132008000500005
  13. Floreth T, 2011, CLIN CHEST MED, V32, P265, DOI 10.1016/j.ccm.2011.02.012
  14. Ganesan S, 2013, TISSUE BARRIERS, V1, DOI 10.4161/tisb.24997
  15. Jatene Fabio Biscegli, 2009, REV MED SAO PAULO, V88, P111, DOI 10.11606/issn.1679-9836.v88i3p111-122
  16. Jeffery PK, 1997, EUR RESPIR J, V10, P1655, DOI 10.1183/09031936.97.10071655
  17. Karp NA, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15475
  18. Krempel PG, 2014, INVEST OPHTH VIS SCI, V55, P5109, DOI 10.1167/iovs.14-14466
  19. Li RJ, 2007, REGUL TOXICOL PHARM, V48, P284, DOI 10.1016/j.yrtph.2007.04.009
  20. Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
  21. McFadden PM, 1998, SURG CLIN N AM, V78, P749, DOI 10.1016/S0039-6109(05)70348-0
  22. MILNE DS, 1994, TRANSPLANTATION, V57, P1757, DOI 10.1097/00007890-199406270-00013
  23. Nie YC, 2012, PULM PHARMACOL THER, V25, P349, DOI 10.1016/j.pupt.2012.06.004
  24. Silva VFPE, 2011, CLINICS, V66, P1451, DOI 10.1590/S1807-59322011000800024
  25. Pazetti R, 2008, ANN THORAC SURG, V85, P1925, DOI 10.1016/j.athoracsur.2008.02.084
  26. Pazetti R, 2007, CLINICS, V62, P345, DOI 10.1590/S1807-59322007000300021
  27. Silva MPE, 2013, ANN THORAC SURG, V96, P473, DOI 10.1016/j.athoracsur.2013.04.069
  28. Rivero DHRF, 2001, CHEST, V119, P1510, DOI 10.1378/chest.119.5.1510
  29. Rogers DF, 2007, RESP CARE, V52, P1134
  30. Rose MC, 2006, PHYSIOL REV, V86, P245, DOI 10.1152/physrev.00010.2005
  31. SAMET JM, 1994, ENVIRON HEALTH PERSP, V102, P89, DOI 10.2307/3431824
  32. Scheffert JL, 2014, J THORAC DIS, V6, P1039, DOI 10.3978/j.issn.2072-1439.2014.04.23
  33. Symmes BA, 2018, BIOCHEM SOC T, V46, P707, DOI 10.1042/BST20170455
  34. Vincenti F, 2006, TRANSPL INT, V19, P446, DOI 10.1111/j.1432-2277.2006.00321.x
  35. Xavier AM, 2007, ACTA CIR BRAS, V22, P465, DOI 10.1590/S0102-86502007000600009
  36. Xia JH, 2003, CHINESE MED J-PEKING, V116, P432

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - HC/InRad
Artigos e Materiais de Revistas Científicas - LIM/20
Artigos e Materiais de Revistas Científicas - LIM/61